GM1 Gangliosidosis
Symptoms, Doctors, Treatments, Advances & More

Learn About GM1 Gangliosidosis

What is the definition of GM1 Gangliosidosis?

GM1 gangliosidosis is an inherited disorder that destroys nerve cells (neurons) in the brain and spinal cord. This condition can be classified as one of three major types based on the age at which signs and symptoms first appear. However, the signs and symptoms of these three types can overlap, leading some researchers to believe that GM1 gangliosidosis occurs on a spectrum instead of as three distinct types.

What are the causes of GM1 Gangliosidosis?

Variants (also called mutations) in the GLB1 gene cause GM1 gangliosidosis. The GLB1 gene provides instructions for making an enzyme called beta-galactosidase (β-galactosidase). This enzyme is found in lysosomes, which are compartments within cells that break down and recycle different types of molecules. β-galactosidase helps break down several molecules, including a substance called GM1 ganglioside. GM1 ganglioside is important for normal functioning of neurons in the brain.

How prevalent is GM1 Gangliosidosis?

GM1 gangliosidosis is estimated to occur in 1 in 100,000 to 200,000 newborns. Type I is reported more frequently than the other forms of this condition. Most individuals with type III are of Japanese descent.

Is GM1 Gangliosidosis an inherited disorder?

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell must have a variant to cause the disorder. The parents of an individual with an autosomal recessive condition each carry one copy of the altered gene, but they typically do not show signs and symptoms of the condition.

Who are the top GM1 Gangliosidosis Local Doctors?
Elite in GM1 Gangliosidosis
Medical Genetics
Elite in GM1 Gangliosidosis
Medical Genetics
Referral may be required
111 Michigan Ave Nw, 
Washington, DC 
Languages Spoken:
English

Cynthia Tifft is a Medical Genetics provider practicing medicine in Washington, Washington, D.c.. Dr. Tifft is rated as an Elite provider by MediFind in the treatment of GM1 Gangliosidosis. She is also highly rated in 11 other conditions, according to our data. Her clinical expertise encompasses Sandhoff Disease, Gangliosidosis, GM1 Gangliosidosis, and Tay-Sachs Disease.

Elite in GM1 Gangliosidosis
Pediatric Neurology
Elite in GM1 Gangliosidosis
Pediatric Neurology
Referral may be required

Children's National Hospital

1400 Forest Glen Rd Ste 335, 
Silver Spring, MD 
Languages Spoken:
English

Maria Acosta is a Pediatric Neurologist practicing medicine in Silver Spring, Maryland. Dr. Acosta is rated as an Elite provider by MediFind in the treatment of GM1 Gangliosidosis. She is also highly rated in 3 other conditions, according to our data. Her clinical expertise encompasses GM1 Gangliosidosis, Neurofibromatosis, Sandhoff Disease, and Autism Spectrum Disorder.

 
 
 
 
Learn about our expert tiers
Learn More
Experienced in GM1 Gangliosidosis
Family Medicine
Experienced in GM1 Gangliosidosis
Family Medicine

Tower Health Medical Group Family Medicine - West Lawn

2209 Quarry Dr, Ste C34, 
West Lawn, PA 
Languages Spoken:
English
Offers Telehealth

Charles Givens is a primary care provider, practicing in Family Medicine in West Lawn, Pennsylvania. Dr. Givens is rated as an Experienced provider by MediFind in the treatment of GM1 Gangliosidosis. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Hypertension, Familial Hypertension, Glucocorticoid-Remediable Aldosteronism, and Lung Metastases. Dr. Givens is board certified in American Board Of Family Medicine.

What are the latest GM1 Gangliosidosis Clinical Trials?
Match to trials
Find the right clinical trials for you in under a minute
Get started
18-month Double-blind, Randomized, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease and in Late-infantile and Juvenile-onset Forms of GM1 Gangliosidosis or GM2 Gangliosidosis

Summary: An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick type C disease and in late-infantile and juvenile-onset forms of GM1 gangliosidosis or GM2 gangliosidosis

Who are the sources who wrote this article ?

Published Date: April 26, 2023
Published By: National Institutes of Health